At the centennial of Michaelis and Menten, competing Michaelis-Menten steps explain effect of GLP-1 on blood-brain transfer and metabolism of glucose

Basic and Clinical Pharmacology and Toxicology

Volumn 115, Issue 2, 2014, Pages 162-171

  Gejl, Michael ^a,b   Rungby, Jørgen ^c   Brock, Birgitte ^a,d   Gjedde, Albert ^e,f,g  

^a AARHUS UNIVERSITY   (Denmark)

^b UNIVERSITY OF QUEENSLAND   (Australia)

^c GENTOFTE UNIVERSITY HOSPITAL   (Denmark)

^d AARHUS UNIVERSITY HOSPITAL   (Denmark)

^e UNIVERSITY OF COPENHAGEN   (Denmark)

^f MCGILL UNIVERSITY   (Canada)

^g JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADVANCED GLYCATION END PRODUCT; GLUCAGON LIKE PEPTIDE 1; GLUCOSE; GLUCOSE TRANSPORTER 1; GLUCOSE TRANSPORTER 3; GLUCOSE TRANSPORTER 5; HEXOKINASE; INSULIN; MITOGEN ACTIVATED PROTEIN KINASE; REACTIVE OXYGEN METABOLITE; ANTIDIABETIC AGENT; GLUCAGON RECEPTOR; GLUCAGON-LIKE PEPTIDE-1 RECEPTOR;

APPETITE; BLOOD BRAIN BARRIER; BRAIN DISEASE; BRAIN METABOLISM; CEREBROVASCULAR ACCIDENT; DEGENERATIVE DISEASE; ENERGY METABOLISM; ENZYME KINETICS; GLUCOSE BRAIN LEVEL; GLUCOSE METABOLISM; GLUCOSE TRANSPORT; HUMAN; HYPERGLYCEMIA; HYPOGLYCEMIA; IMPAIRED GLUCOSE TOLERANCE; INSULIN BLOOD LEVEL; MICHAELIS MENTEN KINETICS; NON INSULIN DEPENDENT DIABETES MELLITUS; PRIORITY JOURNAL; REVIEW; SATIETY; STEADY STATE; ANIMAL; BRAIN; DIABETES MELLITUS, TYPE 2; METABOLISM; PATHOPHYSIOLOGY; TRANSPORT AT THE CELLULAR LEVEL;

ANIMALS; BIOLOGICAL TRANSPORT; BLOOD-BRAIN BARRIER; BRAIN; DIABETES MELLITUS, TYPE 2; GLUCAGON-LIKE PEPTIDE 1; GLUCOSE; HUMANS; HYPOGLYCEMIC AGENTS; NEURODEGENERATIVE DISEASES; RECEPTORS, GLUCAGON; STROKE;

EID: 84904338002     PISSN: 17427835     EISSN: 17427843     Source Type: Journal    
DOI: 10.1111/bcpt.12240     Document Type: Review

References (130)

1. Kahn SE, Hull RL, Utzschneider KM. Mechanisms linking obesity to insulin resistance and type 2 diabetes. Nature 2006;444:840-6.
2. Nauck MA, Vardarli I, Deacon CF, Holst JJ, Meier JJ. Secretion of glucagon-like peptide-1 (GLP-1) in type 2 diabetes: what is up, what is down? Diabetologia 2011;54:10-8.
3. Morrish NJ, Wang SL, Stevens LK, Fuller JH, Keen H. Mortality and causes of death in the WHO Multinational Study of Vascular Disease in Diabetes. Diabetologia 2001;44(Suppl 2):S14-21.
4. Luchsinger JA, Reitz C, Honig LS, Tang MX, Shea S, Mayeux R. Aggregation of vascular risk factors and risk of incident Alzheimer disease. Neurology 2005;65:545-51.
5. Xu WL, von Strauss E, Qiu CX, Winblad B, Fratiglioni L. Uncontrolled diabetes increases the risk of Alzheimer's disease: a population-based cohort study. Diabetologia 2009;52:1031-9.
6. The Diabetes Control and Complications Trial Research Group. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. The Diabetes Control and Complications Trial Research Group. N Engl J Med 1993;329:977-86.
7. Nathan DM, Zinman B, Cleary PA, Backlund JY, Genuth S, Miller R et al. Modern-day clinical course of type 1 diabetes mellitus after 30 years' duration: the diabetes control and complications trial/epidemiology of diabetes interventions and complications and Pittsburgh epidemiology of diabetes complications experience (1983-2005). Arch Intern Med 2009;169:1307-16.
8. Holman RR, Paul SK, Bethel MA, Matthews DR, Neil HA. 10-year follow-up of intensive glucose control in type 2 diabetes. N Engl J Med 2008;359:1577-89.
9. UK Prospective Diabetes Study (UKPDS) Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group. Lancet 1998;352:837-53.
10. Finfer S, Chittock DR, Su SY, Blair D, Foster D, Dhingra V et al. Intensive versus conventional glucose control in critically ill patients. N Engl J Med 2009;360:1283-97.
11. Novak U, Wilks A, Buell G, McEwen S. Identical mRNA for preproglucagon in pancreas and gut. Eur J Biochem 1987;164:553-8.
12. Holst JJ, Burcelin R, Nathanson E. Neuroprotective properties of GLP-1: theoretical and practical applications. Curr Med Res Opin 2011;27:547-58.
13. Baggio LL, Drucker DJ. Biology of incretins: GLP-1 and GIP. Gastroenterology 2007;132:2131-57.
14. Orskov C, Rabenhoj L, Wettergren A, Kofod H, Holst JJ. Tissue and plasma concentrations of amidated and glycine-extended glucagon-like peptide I in humans. Diabetes 1994;43:535-9.
15. Meier JJ, Nauck MA, Kranz D, Holst JJ, Deacon CF, Gaeckler D et al. Secretion, degradation, and elimination of glucagon-like peptide 1 and gastric inhibitory polypeptide in patients with chronic renal insufficiency and healthy control subjects. Diabetes 2004;53:654-62.
16. Thorens B. Expression cloning of the pancreatic beta cell receptor for the gluco-incretin hormone glucagon-like peptide 1. Proc Natl Acad Sci USA 1992;89:8641-5.
17. Wei Y, Mojsov S. Distribution of GLP-1 and PACAP receptors in human tissues. Acta Physiol Scand 1996;157:355-7.
18. Korner M, Stockli M, Waser B, Reubi JC. GLP-1 receptor expression in human tumors and human normal tissues: potential for in vivo targeting. J Nucl Med 2007;48:736-43.
19. Gromada J, Brock B, Schmitz O, Rorsman P. Glucagon-like Peptide-1: regulation of insulin secretion and therapeutic potential. Basic Clin Pharmacol Toxicol 2004;95:252-62.
20. Panjwani N, Mulvihill EE, Longuet C, Yusta B, Campbell JE, Brown TJ et al. GLP-1 receptor activation indirectly reduces hepatic lipid accumulation but does not attenuate development of atherosclerosis in diabetic male ApoE(-/-) mice. Endocrinology 2013;154:127-39.
21. Pyke C, Knudsen LB. The glucagon-like peptide-1 receptor-or not? Endocrinology 2013;154:4-8.
22. Drucker DJ. The role of gut hormones in glucose homeostasis. J Clin Invest 2007;117:24-32.
23. Creutzfeldt W, Ebert R. New developments in the incretin concept. Diabetologia 1985;28:565-73.
24. Meier JJ, Nauck MA. Glucagon-like peptide 1(GLP-1) in biology and pathology. Diabetes Metab Res Rev 2005;21:91-117.
25. Nauck MA, Heimesaat MM, Behle K, Holst JJ, Nauck MS, Ritzel R et al. Effects of glucagon-like peptide 1 on counterregulatory hormone responses, cognitive functions, and insulin secretion during hyperinsulinemic, stepped hypoglycemic clamp experiments in healthy volunteers. J Clin Endocrinol Metab 2002;87:1239-46.
26. Degn KB, Brock B, Juhl CB, Djurhuus CB, Grubert J, Kim D et al. Effect of intravenous infusion of exenatide (synthetic exendin-4) on glucose-dependent insulin secretion and counterregulation during hypoglycemia. Diabetes 2004;53:2397-403.
27. Holst JJ. The physiology of glucagon-like peptide 1. Physiol Rev 2007;87:1409-39.
28. Lerche S, Soendergaard L, Rungby J, Moeller N, Holst JJ, Schmitz OE et al. No increased risk of hypoglycaemic episodes during 48 h of subcutaneous glucagon-like-peptide-1 administration in fasting healthy subjects. Clin Endocrinol (Oxf) 2009;71:500-6.
29. Gejl M, Lerche S, Egefjord L, Brock B, Moller N, Vang K et al. Glucagon-like peptide-1 (GLP-1) raises blood-brain glucose transfer capacity and hexokinase activity in human brain. Front Neuroenergetics 2013;5:2.
30. Gejl M, Lerche S, Mengel A, Moller N, Bibby BM, Smidt K et al. Influence of GLP-1 on myocardial glucose metabolism in healthy men during normo- or hypoglycemia. PLoS One 2014;9:e83758.
31. Ahren B, Schweizer A, Dejager S, Dunning BE, Nilsson PM, Persson M et al. Vildagliptin enhances islet responsiveness to both hyper- and hypoglycemia in patients with type 2 diabetes. J Clin Endocrinol Metab 2009;94:1236-43.
32. Shyangdan DS, Royle P, Clar C, Sharma P, Waugh N, Snaith A. Glucagon-like peptide analogues for type 2 diabetes mellitus. Cochrane Database Syst Rev 2011;10:CD006423.
33. Garber AJ. Incretin effects on beta-cell function, replication, and mass: the human perspective. Diabetes Care 2011;34(Suppl 2):S258-63.
34. Ahren B. GLP-1 and extra-islet effects. Horm Metab Res 2004;36:842-5.
35. Tong J, Sandoval DA. Is the GLP-1 system a viable therapeutic target for weight reduction? Rev Endocr Metab Disord 2011;12:187-95.
36. Erlanson-Albertsson C. How palatable food disrupts appetite regulation. Basic Clin Pharmacol Toxicol 2005;97:61-73.
37. Holst JJ. On the physiology of GIP and GLP-1. Horm Metab Res 2004;36:747-54.
38. Verdich C, Flint A, Gutzwiller JP, Naslund E, Beglinger C, Hellstrom PM et al. A meta-analysis of the effect of glucagon-like peptide-1 (7-36) amide on ad libitum energy intake in humans. J Clin Endocrinol Metab 2001;86:4382-9.
39. Flint A, Raben A, Astrup A, Holst JJ. Glucagon-like peptide 1 promotes satiety and suppresses energy intake in humans. J Clin Invest 1998;101:515-20.
40. Cabou C, Campistron G, Marsollier N, Leloup C, Cruciani-Guglielmacci C, Penicaud L et al. Brain glucagon-like peptide-1 regulates arterial blood flow, heart rate, and insulin sensitivity. Diabetes 2008;57:2577-87.
41. Shalev A, Holst JJ, Keller U. Effects of glucagon-like peptide 1 (7-36 amide) on whole-body protein metabolism in healthy man. Eur J Clin Invest 1997;27:10-6.
42. Shalev A, Ninnis R, Keller U. Effects of glucagon-like peptide 1 (7-36 amide) on glucose kinetics during somatostatin-induced suppression of insulin secretion in healthy men. Horm Res 1998;49:221-5.
43. Yamamoto H, Lee CE, Marcus JN, Williams TD, Overton JM, Lopez ME et al. Glucagon-like peptide-1 receptor stimulation increases blood pressure and heart rate and activates autonomic regulatory neurons. J Clin Invest 2002;110:43-52.
44. Nogueiras R, Perez-Tilve D, Veyrat-Durebex C, Morgan DA, Varela L, Haynes WG et al. Direct control of peripheral lipid deposition by CNS GLP-1 receptor signaling is mediated by the sympathetic nervous system and blunted in diet-induced obesity. J Neurosci 2009;29:5916-25.
45. Lockie SH, Heppner KM, Chaudhary N, Chabenne JR, Morgan DA, Veyrat-Durebex C et al. Direct control of brown adipose tissue thermogenesis by central nervous system glucagon-like peptide-1 receptor signaling. Diabetes 2012;61:2753-62.
46. Osaka T, Endo M, Yamakawa M, Inoue S. Energy expenditure by intravenous administration of glucagon-like peptide-1 mediated by the lower brainstem and sympathoadrenal system. Peptides 2005;26:1623-31.
47. Pannacciulli N, Bunt JC, Koska J, Bogardus C, Krakoff J. Higher fasting plasma concentrations of glucagon-like peptide 1 are associated with higher resting energy expenditure and fat oxidation rates in humans. Am J Clin Nutr 2006;84:556-60.
48. Nauck M, Stockmann F, Ebert R, Creutzfeldt W. Reduced incretin effect in type 2 (non-insulin-dependent) diabetes. Diabetologia 1986;29:46-52.
49. Nauck MA, Kleine N, Orskov C, Holst JJ, Willms B, Creutzfeldt W. Normalization of fasting hyperglycaemia by exogenous glucagon-like peptide 1 (7-36 amide) in type 2 (non-insulin-dependent) diabetic patients. Diabetologia 1993;36:741-4.
50. Huang A, Raskin P. Glucagon-like peptide: the time is near. Basic Clin Pharmacol Toxicol 2004;95:249-51.
51. Sokos GG, Nikolaidis LA, Mankad S, Elahi D, Shannon RP. Glucagon-like peptide-1 infusion improves left ventricular ejection fraction and functional status in patients with chronic heart failure. J Card Fail 2006;12:694-9.
52. Gejl M, Sondergaard HM, Stecher C, Bibby BM, Moller N, Botker HE et al. Exenatide alters myocardial glucose transport and uptake depending on insulin resistance and increases myocardial blood flow in patients with type 2 diabetes. J Clin Endocrinol Metab 2012;97:E1165-9.
53. Angeli FS, Shannon RP. Incretin based therapies: can we achieve glycemic control and cardioprotection? J Endocrinol 2013;221:T17-30.
54. Hamilton A, Holscher C. Receptors for the incretin glucagon-like peptide-1 are expressed on neurons in the central nervous system. NeuroReport 2009;20:1161-6.
55. Goke R, Larsen PJ, Mikkelsen JD, Sheikh SP. Distribution of GLP-1 binding sites in the rat brain: evidence that exendin-4 is a ligand of brain GLP-1 binding sites. Eur J Neurosci 1995;7:2294-300.
56. Wei Y, Mojsov S. Tissue-specific expression of the human receptor for glucagon-like peptide-I: brain, heart and pancreatic forms have the same deduced amino acid sequences. FEBS Lett 1995;358:219-24.
57. Alvarez E, Martinez MD, Roncero I, Chowen JA, Garcia-Cuartero B, Gispert JD et al. The expression of GLP-1 receptor mRNA and protein allows the effect of GLP-1 on glucose metabolism in the human hypothalamus and brainstem. J Neurochem 2005;92:798-806.
58. Thorens B. Physiology of GLP-1-lessons from glucoincretin receptor knockout mice. Horm Metab Res 2004;36:766-70.
59. Hayes MR. Neuronal and intracellular signaling pathways mediating GLP-1 energy balance and glycemic effects. Physiol Behav 2012;106:413-6.
60. Perry T, Lahiri DK, Chen D, Zhou J, Shaw KT, Egan JM et al. A novel neurotrophic property of glucagon-like peptide 1: a promoter of nerve growth factor-mediated differentiation in PC12 cells. J Pharmacol Exp Ther 2002;300:958-66.
61. During MJ, Cao L, Zuzga DS, Francis JS, Fitzsimons HL, Jiao X et al. Glucagon-like peptide-1 receptor is involved in learning and neuroprotection. Nat Med 2003;9:1173-9.
62. Perry T, Holloway HW, Weerasuriya A, Mouton PR, Duffy K, Mattison JA et al. Evidence of GLP-1-mediated neuroprotection in an animal model of pyridoxine-induced peripheral sensory neuropathy. Exp Neurol 2007;203:293-301.
63. Li Y, Perry T, Kindy MS, Harvey BK, Tweedie D, Holloway HW et al. GLP-1 receptor stimulation preserves primary cortical and dopaminergic neurons in cellular and rodent models of stroke and Parkinsonism. Proc Natl Acad Sci USA 2009;106:1285-90.
64. Popa-Wagner A, Mitran S, Sivanesan S, Chang E, Buga AM. ROS and brain diseases: the good, the bad, and the ugly. Oxid Med Cell Longev 2013;2013:963520.
65. Egefjord L, Gejl M, Moller A, Braendgaard H, Gottrup H, Antropova O et al. Effects of liraglutide on neurodegeneration, blood flow and cognition in Alzheimer s disease - protocol for a controlled, randomized double-blinded trial. Dan Med J 2012;59:A4519.
66. Holscher C. Central effects of GLP-1: new opportunities for treatments of neurodegenerative diseases. J Endocrinol 2014;221:T31-41.
67. Popa-Wagner A, Buga AM, Popescu B, Muresanu D. Vascular cognitive impairment, dementia, aging and energy demand. A vicious cycle. J Neural Transm 2013; doi: 10.1007/s00702-013-1129-3. [Epub ahead of print].
68. Orskov C, Poulsen SS, Moller M, Holst JJ. Glucagon-like peptide I receptors in the subfornical organ and the area postrema are accessible to circulating glucagon-like peptide I. Diabetes 1996;45:832-5.
69. Kastin AJ, Akerstrom V, Pan W. Interactions of glucagon-like peptide-1 (GLP-1) with the blood-brain barrier. J Mol Neurosci 2002;18:7-14.
70. Kastin AJ, Akerstrom V. Entry of exendin-4 into brain is rapid but may be limited at high doses. Int J Obes Relat Metab Disord 2003;27:313-8.
71. Schwartz MW, Porte D Jr. Diabetes, obesity, and the brain. Science 2005;307:375-9.
72. Knauf C, Cani PD, Kim DH, Iglesias MA, Chabo C, Waget A et al. Role of central nervous system glucagon-like Peptide-1 receptors in enteric glucose sensing. Diabetes 2008;57:2603-12.
73. Sandoval DA, Bagnol D, Woods SC, D'Alessio DA, Seeley RJ. Arcuate glucagon-like peptide 1 receptors regulate glucose homeostasis but not food intake. Diabetes 2008;57:2046-54.
74. Sokoloff L, Reivich M, Kennedy C, Des Rosiers MH, Patlak CS, Pettigrew KD et al. The [14C]deoxyglucose method for the measurement of local cerebral glucose utilization: theory, procedure, and normal values in the conscious and anesthetized albino rat. J Neurochem 1977;28:897-916.
75. Lassen NA, Ingvar DH, Skinhoj E. Brain function and blood flow. Sci Am 1978;239:62-71.
76. Landau WM, Freygang WH Jr, Roland LP, Sokoloff L. KETY SS. The local circulation of the living brain; values in the unanesthetized and anesthetized cat. Trans Am Neurol Assoc 1955;(80th Meeting):125-9.
77. Ter-Pogossian MM, Herscovitch P. Radioactive oxygen-15 in the study of cerebral blood flow, blood volume, and oxygen metabolism. Semin Nucl Med 1985;15:377-94.
78. Raichle ME. Functional brain imaging and human brain function. J Neurosci 2003;23:3959-62.
79. Leybaert L. Neurobarrier coupling in the brain: a partner of neurovascular and neurometabolic coupling? J Cereb Blood Flow Metab 2005;25:2-16.
80. Gejl M, Egefjord L, Lerche S, Vang K, Bibby BM, Holst JJ et al. Glucagon-like peptide-1 decreases intracerebral glucose content by activating hexokinase and changing glucose clearance during hyperglycemia. J Cereb Blood Flow Metab 2012;32:2146-52.
81. McCall AL. Cerebral glucose metabolism in diabetes mellitus. Eur J Pharmacol 2004;490:147-58.
82. Crone C. Facilitated transfer of glucose from blood into brain tissue. J Physiol 1965;181:103-13.
83. Pardridge WM. Brain metabolism: a perspective from the blood-brain barrier. Physiol Rev 1983;63:1481-535.
84. van Donkelaar EL, Ferrington L, Blokland A, Steinbusch HW, Prickaerts J, Kelly PA. Acute tryptophan depletion in rats alters the relationship between cerebral blood flow and glucose metabolism independent of central serotonin. Neuroscience 2009;163:683-94.
85. Howarth C, Gleeson P, Attwell D. Updated energy budgets for neural computation in the neocortex and cerebellum. J Cereb Blood Flow Metab 2012;32:1222-32.
86. Kann O, Kovacs R. Mitochondria and neuronal activity. Am J Physiol Cell Physiol 2007;292:C641-57.
87. Moreira PI, Duarte AI, Santos MS, Rego AC, Oliveira CR. An integrative view of the role of oxidative stress, mitochondria and insulin in Alzheimer's disease. J Alzheimers Dis 2009;16:741-61.
88. Mergenthaler P, Lindauer U, Dienel GA, Meisel A. Sugar for the brain: the role of glucose in physiological and pathological brain function. Trends Neurosci 2013;36:587-97.
89. Russo VC, Higgins S, Werther GA, Cameron FJ. Effects of fluctuating glucose levels on neuronal cells in vitro. Neurochem Res 2012;37:1768-82.
90. Gjedde A, Christensen O. Estimates of Michaelis-Menten constants for the two membranes of the brain endothelium. J Cereb Blood Flow Metab 1984;4:241-9.
91. Lindsberg PJ, Roine RO. Hyperglycemia in acute stroke. Stroke 2004;35:363-4.
92. Bellolio MF, Gilmore RM, Stead LG. Insulin for glycaemic control in acute ischaemic stroke. Cochrane Database Syst Rev 2011;9:CD005346.
93. Brands AM, Kessels RP, de Haan EH, Kappelle LJ, Biessels GJ. Cerebral dysfunction in type 1 diabetes: effects of insulin, vascular risk factors and blood-glucose levels. Eur J Pharmacol 2004;490:159-68.
94. Humpel C. Chronic mild cerebrovascular dysfunction as a cause for Alzheimer's disease? Exp Gerontol 2011;46:225-32.
95. Michaelis L, Menten ML. Die Kinetik der Invertinwirkung. Biochem Z 1913;49:333-69.
96. Gjedde A, Crone C. Blood-brain glucose transfer: repression in chronic hyperglycemia. Science 1981;214:456-7.
97. Hasselbalch SG, Knudsen GM, Capaldo B, Postiglione A, Paulson OB. Blood-brain barrier transport and brain metabolism of glucose during acute hyperglycemia in humans. J Clin Endocrinol Metab 2001;86:1986-90.
98. Blomqvist G, Gjedde A, Gutniak M, Grill V, Widen L, Stone-Elander S et al. Facilitated transport of glucose from blood to brain in man and the effect of moderate hypoglycaemia on cerebral glucose utilization. Eur J Nucl Med 1991;18:834-7.
99. Hasselbalch SG, Knudsen GM, Videbaek C, Pinborg LH, Schmidt JF, Holm S et al. No effect of insulin on glucose blood-brain barrier transport and cerebral metabolism in humans. Diabetes 1999;48:1915-21.
100. Vannucci SJ, Maher F, Koehler E, Simpson IA. Altered expression of GLUT-1 and GLUT-3 glucose transporters in neurohypophysis of water-deprived or diabetic rats. Am J Physiol 1994;267(4 Pt 1):E605-11.
101. Cameron FJ, Baghurst PA, Rodbard D. Assessing glycemic variation: why, when and how? Pediatr Endocrinol Rev 2010;7(Suppl 3):432-44.
102. Nalysnyk L, Hernandez-Medina M, Krishnarajah G. Glycaemic variability and complications in patients with diabetes mellitus: evidence from a systematic review of the literature. Diabetes Obes Metab 2010;12:288-98.
103. Siegelaar SE, Holleman F, Hoekstra JB, DeVries JH. Glucose variability; does it matter? Endocr Rev 2010;31:171-82.
104. Burmeister MA, Ayala J, Drucker DJ, Ayala JE. Central glucagon-like peptide 1 receptor-induced anorexia requires glucose metabolism-mediated suppression of AMPK and is impaired by central fructose. Am J Physiol Endocrinol Metab 2013;304:E677-85.
105. Lim JG, Lee JJ, Park SH, Park JH, Kim SJ, Cho HC et al. Glucagon-like peptide-1 protects NSC-34 motor neurons against glucosamine through Epac-mediated glucose uptake enhancement. Neurosci Lett 2010;479:13-7.
106. Hardie DG, Ross FA, Hawley SA. AMPK: a nutrient and energy sensor that maintains energy homeostasis. Nat Rev Mol Cell Biol 2012;13:251-62.
107. Bomba M, Ciavardelli D, Silvestri E, Canzoniero LM, Lattanzio R, Chiappini P et al. Exenatide promotes cognitive enhancement and positive brain metabolic changes in PS1-KI mice but has no effects in 3xTg-AD animals. Cell Death Dis 2013;4:e612.
108. Lerche S, Brock B, Rungby J, Botker HE, Moller N, Rodell A et al. Glucagon-like peptide-1 inhibits blood-brain glucose transfer in humans. Diabetes 2008;57:325-31.
109. Guo H, Renaut RA, Chen K. An input function estimation method for FDG-PET human brain studies. Nucl Med Biol 2007;34:483-92.
110. Chen K, Bandy D, Reiman E, Huang SC, Lawson M, Feng D et al. Noninvasive quantification of the cerebral metabolic rate for glucose using positron emission tomography, 18F-fluoro-2-deoxyglucose, the Patlak method, and an image-derived input function. J Cereb Blood Flow Metab 1998;18:716-23.
111. Kennan RP, Takahashi K, Pan C, Shamoon H, Pan JW. Human cerebral blood flow and metabolism in acute insulin-induced hypoglycemia. J Cereb Blood Flow Metab 2005;25:527-34.
112. Grieve DJ, Cassidy RS, Green BD. Emerging cardiovascular actions of the incretin hormone glucagon-like peptide-1: potential therapeutic benefits beyond glycaemic control? Br J Pharmacol 2009;157:1340-51.
113. Bak AM, Egefjord L, Gejl M, Steffensen C, Stecher CW, Smidt K et al. Targeting amyloid-beta by glucagon-like peptide -1 (GLP-1) in Alzheimer's disease and diabetes. Expert Opin Ther Targets 2011;15:1153-62.
114. Darsalia V, Mansouri S, Ortsater H, Olverling A, Nozadze N, Kappe C et al. Glucagon-like peptide-1 receptor activation reduces ischaemic brain damage following stroke in Type 2 diabetic rats. Clin Sci (Lond) 2012;122:473-83.
115. Hom FG, Goodner CJ, Berrie MA. A [3H]2-deoxyglucose method for comparing rates of glucose metabolism and insulin responses among rat tissues in vivo. Validation of the model and the absence of an insulin effect on brain. Diabetes 1984;33:141-52.
116. McCall AL, Gould JB, Ruderman NB. Diabetes-induced alterations of glucose metabolism in rat cerebral microvessels. Am J Physiol 1984;247(4 Pt 1):E462-7.
117. Namba H, Lucignani G, Nehlig A, Patlak C, Pettigrew K, Kennedy C et al. Effects of insulin on hexose transport across blood-brain barrier in normoglycemia. Am J Physiol 1987;252(3 Pt 1):E299-303.
118. Seaquist ER, Damberg GS, Tkac I, Gruetter R. The effect of insulin on in vivo cerebral glucose concentrations and rates of glucose transport/metabolism in humans. Diabetes 2001;50:2203-9.
119. Shapiro ET, Cooper M, Chen CT, Given BD, Polonsky KS. Change in hexose distribution volume and fractional utilization of [18F]-2-deoxy-2-fluoro-D-glucose in brain during acute hypoglycemia in humans. Diabetes 1990;39:175-80.
120. Hertz MM, Paulson OB, Barry DI, Christiansen JS, Svendsen PA. Insulin increases glucose transfer across the blood-brain barrier in man. J Clin Invest 1981;67:597-604.
121. Hirvonen J, Virtanen KA, Nummenmaa L, Hannukainen JC, Honka MJ, Bucci M et al. Effects of insulin on brain glucose metabolism in impaired glucose tolerance. Diabetes 2011;60:443-7.
122. Banks WA, Owen JB, Erickson MA. Insulin in the brain: there and back again. Pharmacol Ther 2012;136:82-93.
123. Hallschmid M, Schultes B. Central nervous insulin resistance: a promising target in the treatment of metabolic and cognitive disorders? Diabetologia 2009;52:2264-9.
124. Laron Z. Insulin and the brain. Arch Physiol Biochem 2009;115:112-6.
125. Cardoso S, Correia S, Santos RX, Carvalho C, Santos MS, Oliveira CR et al. Insulin is a two-edged knife on the brain. J Alzheimers Dis 2009;18:483-507.
126. van der Heide LP, Ramakers GM, Smidt MP. Insulin signaling in the central nervous system: learning to survive. Prog Neurobiol 2006;79:205-21.
127. Bingham EM, Hopkins D, Smith D, Pernet A, Hallett W, Reed L et al. The role of insulin in human brain glucose metabolism: an 18fluoro-deoxyglucose positron emission tomography study. Diabetes 2002;51:3384-90.
128. Anthony K, Reed LJ, Dunn JT, Bingham E, Hopkins D, Marsden PK et al. Attenuation of insulin-evoked responses in brain networks controlling appetite and reward in insulin resistance: the cerebral basis for impaired control of food intake in metabolic syndrome? Diabetes 2006;55:2986-92.
129. Wang WT, Lee P, Yeh HW, Smirnova IV, Choi IY. Effects of acute and chronic hyperglycemia on the neurochemical profiles in the rat brain with streptozotocin-induced diabetes detected using in vivo (1)H MR spectroscopy at 9.4 T. J Neurochem 2012;121:407-17.
130. Johnson KA, Fox NC, Sperling RA, Klunk WE. Brain imaging in Alzheimer disease. Cold Spring Harb Perspect Med 2012;2:a006213.